Cognition Therapeutics Inc. (NASDAQ: CGTX) published results from its Phase 2 clinical trial of zervimesine in the journal Alzheimer's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE